# Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies

> **NCT00078195** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 168 (—)

## Conditions studied

- Hay Fever
- Hypersensitivity
- Allergy
- Rhinitis

## Interventions

- **BIOLOGICAL:** omalizumab
- **BIOLOGICAL:** Placebo omalizumab
- **BIOLOGICAL:** Ragweed rush immunotherapy (RIT)
- **BIOLOGICAL:** Placebo rush immunotherapy (RIT)
- **BIOLOGICAL:** Ragweed immunotherapy (IT)
- **BIOLOGICAL:** Placebo immunotherapy (IT)

## Key facts

- **NCT ID:** NCT00078195
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2005-05
- **Final completion:** 2005-05
- **Target enrollment:** 168 (—)
- **Last updated:** 2016-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00078195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00078195, "Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00078195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*